• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

作者信息

Iyevleva Aglaya G, Mitiushkina Natalia V, Karaseva Nina A, Orlov Sergey V, Volodina Larisa N, Kulikova Yulia E, Lozhkina Alexandra M, Ivantsov Alexandr O, Tiurin Vladislav I, Togo Alexandr V, Imyanitov Evgeny N

机构信息

N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia City Oncological Hospital, St. Petersburg, Russia Institute of Pulmonology, St. Petersburg, Russia Regional Oncological Hospital, Ryazan, Russia Institute of Pulmonology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia St. Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia, I.I. Mechnikov North-Western Medical University, St. Petersburg, Russia.

出版信息

J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106.

DOI:10.1097/JTO.0000000000000106
PMID:24736087
Abstract
摘要

相似文献

1
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.具有表皮生长因子受体（EGFR）第19外显子插入的肺癌对吉非替尼治疗敏感。
J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106.
2
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.表皮生长因子受体（EGFR）第19外显子的一种罕见插入突变在酪氨酸激酶抑制剂（TKI）治疗后显示疾病稳定。
J Thorac Oncol. 2013 Dec;8(12):e107-8. doi: 10.1097/JTO.0b013e3182a471e0.
3
EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.表皮生长因子受体（EGFR）第19外显子插入突变在日本患者中对吉非替尼显示出良好的反应，但疾病进展时间较短。
J Thorac Oncol. 2014 Feb;9(2):e10-1. doi: 10.1097/JTO.0b013e3182a735cc.
4
Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.三种 PCR 方法检测晚期非小细胞肺癌患者表皮生长因子受体突变的直接比较。
Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10.
5
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.细胞角蛋白 19 片段可预测 EGFR 突变型非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂的疗效。
J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.
6
Two rare exon 21 EGFR mutations in patients treated with gefitinib.两名接受吉非替尼治疗的患者出现罕见的外显子21表皮生长因子受体（EGFR）突变。
J Thorac Oncol. 2013 Apr;8(4):e36-7. doi: 10.1097/JTO.0b013e318286cf9e.
7
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.比较表皮生长因子受体外显子 19 或 21 突变的非小细胞肺癌患者使用吉非替尼和厄洛替尼治疗的临床结局。
J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
8
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.台湾非小细胞肺癌中表皮生长因子受体突变频率高且模式复杂，与吉非替尼反应性相关
Clin Cancer Res. 2004 Dec 15;10(24):8195-203. doi: 10.1158/1078-0432.CCR-04-1245.
9
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.中国非小细胞肺癌患者表皮生长因子受体酪氨酸激酶结构域的吉非替尼敏感突变
Clin Cancer Res. 2005 Jun 15;11(12):4289-94. doi: 10.1158/1078-0432.CCR-04-2506.
10
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.一种在非小细胞肺癌患者中使用限制性片段长度多态性（RFLP）筛查表皮生长因子受体（EGFR）突变的替代方法。
J Thorac Oncol. 2008 Oct;3(10):1096-103. doi: 10.1097/JTO.0b013e318186fadd.

引用本文的文献

1
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.表皮生长因子受体（EGFR）第19外显子插入的非小细胞肺癌患者的分子特征及对EGFR酪氨酸激酶抑制剂的反应
BMC Med. 2025 Apr 29;23(1):249. doi: 10.1186/s12916-025-04075-1.
2
Current status of molecular diagnostics for lung cancer.肺癌分子诊断的现状
Explor Target Antitumor Ther. 2024;5(3):742-765. doi: 10.37349/etat.2024.00244. Epub 2024 Jun 27.
3
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
EGFR 外显子 19 插入 EGFR-K745_E746insIPVAIK 和其他罕见的 XPVAIK 氨基酸插入：所有批准的 EGFR 激酶抑制剂的有利治疗窗口的临床前和临床特征。
Lung Cancer. 2023 Jul;181:107250. doi: 10.1016/j.lungcan.2023.107250. Epub 2023 May 13.
4
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.非小细胞肺癌的治疗进展：聚焦于靶向治疗和免疫治疗的临床开发
MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec.
5
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.携带罕见 EGFR 外显子 19 缺失-插入突变的患者对第一代 EGFR 抑制剂和奥希替尼治疗敏感，奥希替尼是在获得 T790M 后使用的。
BMC Cancer. 2021 Nov 13;21(1):1215. doi: 10.1186/s12885-021-08942-x.
6
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.基于突变测试的癌症治疗：现状与展望。
Int J Mol Sci. 2021 Oct 10;22(20):10931. doi: 10.3390/ijms222010931.
7
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.24468 例中国肺癌患者中 EGFR 外显子 20 插入的变异性及其对 EGFR 抑制剂的不同反应。
Mol Oncol. 2020 Aug;14(8):1695-1704. doi: 10.1002/1878-0261.12710. Epub 2020 Jun 15.
8
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.非小细胞肺癌中罕见的表皮生长因子受体（EGFR）突变。
Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25.
9
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.并非所有肺癌中的表皮生长因子受体突变都是相同的：个体化治疗策略的前景
Cancer Sci. 2016 Sep;107(9):1179-86. doi: 10.1111/cas.12996. Epub 2016 Aug 9.